Group 1 - The company, Four Seasons Pharmaceutical (00460), announced a share buyback plan on October 17, 2025, with an investment of HKD 21.7575 million to repurchase 15 million shares [1]

格隆汇10月17日丨四环医药(00460.HK)公告，10月17日耗资2175.8万港元回购1500万股。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 此 乃 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司， 統 稱 為「本集團」）作 出 的 自 願 公 告。 自願公告 購回股份 超 過60款 的 醫 美 產 品 管 線，覆 蓋 愛 美 人 士 全 生 命 週 期 需 求。截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月，本 集 團 醫 美 業 務 收 入 達 約 人 民 幣585百 萬 元，同 比 增 長 約 81%。此 外，本 集 團 的 創 新 藥 研 發 進 入 收 穫 期。截 至 二 零 二 五 年 九 月 三 十 日 止 九 個 月，本 集 團 共 有15 ...

| 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 00460 | 說明 | 面值港幣 0.01 元普通股 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年10月15日 | | 9,168,988,206 | 161,011,000 | | 9,329,999,206 | | 1). 購回股份 (股份被持作庫存股份) | | | -15,000,000 0.1636 % | 15,000,000 HKD | 1.4505 | | | 變動日期 | 2 ...

Core Viewpoint - The Hong Kong stock market experienced a significant decline, with the Hang Seng Index dropping over 4%, reaching a new low in over a month. In contrast, Xuan Bamboo Biotech (2575.HK), spun off from Sihuan Pharmaceutical, saw its stock price surge by 17.1% to HKD 33.96, marking a new high since its IPO [1]. Company Overview - Xuan Bamboo Biotech is an innovative Chinese biopharmaceutical company focused on improving patient health and life through a deep understanding of the Chinese pharmaceutical industry and its unique clinical needs [1]. - Since its acquisition by Sihuan Pharmaceutical in 2008, Xuan Bamboo has established a comprehensive internal R&D platform that supports the development of a diverse and balanced pipeline of drug candidates [1]. Financial Performance - The stock price of Xuan Bamboo Biotech has increased by 192.76% from its IPO price of HKD 11.6, just three trading days after its debut on the Hong Kong Stock Exchange [1]. Drug Development Pipeline - Xuan Bamboo Biotech currently has over ten drug assets actively in development, targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease (NASH) [1]. - The company has three assets approved for New Drug Application (NDA), one project in the NDA registration stage, one in Phase III clinical trials, four in Phase I clinical trials, and five that have received Investigational New Drug (IND) approval [1].

Core Viewpoint - Xuan Zhu Biotech-B (02575) has seen a significant stock price increase, rising over 190% from its IPO price of 11.6 HKD, reaching a new high of 33.96 HKD, indicating strong market interest and confidence in the company's growth potential [1] Company Overview - Xuan Zhu Biotech is a Chinese biopharmaceutical company backed by the Hong Kong-listed company Sihuan Pharmaceutical, with dual research and development systems for small molecule drugs and large molecule biologics [1] - The company has successfully developed four candidate drugs and is actively developing over ten drug assets targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease (NASH) [1] Product Pipeline - Currently, Xuan Zhu Biotech has three commercialized products: Annelazole sodium for duodenal ulcers, Pyrotinib for breast cancer, and Dirocitinib for non-small cell lung cancer, with approvals expected in 2023 and 2025 [1] Industry Outlook - Huafu Securities believes that the Chinese innovative drug sector is undergoing a transformation, with a positive outlook for the next 5-10 years driven by overseas business development, continuous data catalysts, and the ramp-up of new product sales [1]

Core Viewpoint - XuanZhu Biotech-B (02575) has seen a significant increase in stock price, rising over 11% and reaching a new high of 33.96 HKD, which is more than 190% above its IPO price of 11.6 HKD [1] Company Overview - XuanZhu Biotech is a Chinese biopharmaceutical company backed by Hong Kong-listed company Sihuan Pharmaceutical, with dual research and development systems for small molecule drugs and large molecule biologics [1] - The company has successfully developed four candidate drugs and is actively developing over ten drug assets targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease (NASH) [1] Commercial Products - Currently, XuanZhu Biotech has three commercialized products: Annelazole sodium for duodenal ulcers, Pyrotinib for breast cancer, and Dirocitinib for non-small cell lung cancer, which are expected to be approved in 2023 and 2025 [1] Industry Trends - Huafu Securities believes that the Chinese innovative drug sector is experiencing a transformation driven by quantitative changes leading to qualitative changes, with a positive outlook on the industry trend over the next 5-10 years [1] - Factors such as business development overseas, continuous data catalysts, and the ramp-up of new product sales are expected to drive the rise of innovative drugs [1]

Core Insights - The domestic medical beauty market in China is becoming increasingly competitive, with significant price reductions and patent disputes among leading companies [1][3][6] - Major players are expanding overseas as domestic profit margins shrink, indicating a strategic shift towards international markets [1][11] Market Competition - New Oxygen launched a low-priced "Miracle Youth Needle" at 2999 yuan, significantly undercutting competitors and causing dissatisfaction among upstream material suppliers [3][6] - Huaxi Biological and Juzi Biological are engaged in a fierce dispute over collagen product patents, highlighting the intense competition in the market [3][4] - The competition is characterized by a shift from regulatory competition to market-driven competition, with a growing number of brands entering the space [6][7] Financial Performance - Major companies like Aimeike and Huaxi Biological reported significant declines in revenue and net profit, with Aimeike's revenue and net profit down 21.59% and 29.57% respectively in the first half of the year [7][10] - Huaxi Biological's revenue and net profit also fell by 19.57% and 35.38% respectively, marking a continuous decline over two years [7][10] International Expansion - Chinese medical beauty companies are increasingly looking to international markets, with firms like Aimeike and Huaxi Biological investing in overseas partnerships [1][11] - The strategy involves acquiring or investing in foreign companies to introduce Chinese products to international markets, rather than relying on traditional business development methods [11][12] Emerging Markets - There is a growing opportunity in emerging markets such as Southeast Asia and Latin America, where demand for cost-effective and multifunctional products is rising [12][13] - Companies are focusing on building technological barriers and moving away from the "low-price" label by investing in advanced materials and techniques [13]

Core Insights - The Chinese medical aesthetics market is becoming increasingly competitive, with significant price reductions and patent disputes among leading companies [1][2][3] - Major players are expanding internationally as domestic competition intensifies, with companies like Four Rings Pharmaceutical investing in overseas markets [1][9] - The industry is transitioning from a focus on product registration to market-driven competition, leading to a "price war" and a shift towards a more comprehensive competition model involving product, service, and technology [6][10] Market Dynamics - The medical aesthetics industry in China has evolved from a niche market to a significant sector, but the penetration rate of medical aesthetics products remains low compared to mature markets like Europe and the U.S. [1][6] - New Oxygen's introduction of the "Miracle Youth Needle 3.0" at a price point below 3000 yuan marks a significant price drop in the domestic market [1][2] - The competition among major products such as water light needles, youth needles, and recombinant collagen is intensifying, with numerous new products entering the market [4][6] Financial Performance - Leading companies are experiencing significant revenue declines, with Aimeike reporting a 21.59% drop in revenue and a 29.57% decrease in net profit in the first half of the year [7][8] - Huaxi Biological has also seen a continuous decline in annual performance, with a 19.57% drop in revenue and a 35.38% decrease in net profit in the first half of the year [7][8] International Expansion - Chinese medical aesthetics companies are increasingly looking to international markets for growth, with several firms, including Aimeike and Huaxi Biological, investing in overseas companies [9][10] - The global medical aesthetics market is still in a growth phase, but companies face challenges such as regulatory differences, cultural adaptation, and established local competition [10][12] - Emerging markets in Southeast Asia, the Middle East, and Latin America present opportunities for Chinese companies to expand, as these regions show rapid growth in medical aesthetics consumption [12][13]

Summary of Key Points Core Viewpoint - On October 15, 37 Hong Kong-listed companies conducted share buybacks, totaling 34.04 million shares and an aggregate amount of HKD 167 million [1]. Group 1: Buyback Details - Xiaomi Group-W repurchased 2 million shares for HKD 98.96 million, with a highest price of HKD 49.54 and a lowest price of HKD 49.42, bringing its total buyback amount for the year to HKD 852 million [1][2]. - Four Seasons Pharmaceutical repurchased 10 million shares for HKD 15.19 million, with a highest price of HKD 1.54 and a lowest price of HKD 1.50, totaling HKD 12.16 million in buybacks for the year [1][2]. - Cloud Factory repurchased 2 million shares for HKD 8.01 million, with a highest price of HKD 4.05 and a lowest price of HKD 3.98, accumulating HKD 86.80 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 15 was from Xiaomi Group-W at HKD 98.96 million, followed by Four Seasons Pharmaceutical at HKD 15.19 million [1][2]. - In terms of share quantity, Four Seasons Pharmaceutical led with 10 million shares repurchased, followed by Anton Oilfield Services and China Electric Power Technology with 4.69 million and 4.60 million shares, respectively [1][2]. Group 3: Additional Buyback Information - Morning News Technology conducted its first buyback of the year on this date [2]. - A detailed table of buybacks includes various companies, their respective share counts, buyback amounts, highest and lowest prices, and cumulative buyback amounts for the year [2][3].